Select Page

News Release

Tigermed and AstraZeneca (China) Announced a Strategic Partnership, a Joint Acceleration of Drug Research and Development

July 10, 2019

On July 5, 2019, Tigermed and AstraZeneca (China) signed a strategic cooperation agreement in Shanghai, China, announcing that the two sides will consistently adhere to the concept of “patient-centered” at high degree of consensus and carry out omni-directional strategic cooperation in the process of clinical research and development of innovative pharmaceutical products. Leon Wang, Executive Vice President, International and China President, AstraZeneca, and Dr. Ye Xiaoping, Chairman of Tigermed, attended the signing ceremony.

AstraZeneca (China) and Tigermed, as a global biopharmaceuticals company and industry leading Contract Research Organizations (CRO), have previously worked together at many levels, and Tigermed is also the preferred supplier of AstraZeneca (China). The signing of this strategic cooperation agreement is another elevation of cooperation between the two organizations, and will be another milestone on the road of a long-term close cooperation between AstraZeneca (China) and Tigermed in the future. In accordance with the principle of complementary advantages and earnest cooperation, the two sides will cooperate intensely in clinical trials, registration, data management, statistical analysis, biological analysis / central laboratory, coordination of clinical trial research center, medical writing / medical supervision service, medical imaging, drug vigilance, third-party inspection and training, clinical cold chain logistics and more aspects.

“Tigermed has professional services, rich clinical resources and global service network in the whole process of clinical research of new drugs, and has always adhered to the internationalization strategy of ‘GlOBAL EXCELLENCE CHINA EXPERTISE’, which coincides with AstraZeneca concept and pursuit.” Leon Wang, Executive Vice President, International and China President, AstraZeneca. He expressed deep appreciation for the one-stop service of clinical research and the positive global layout of Tigermed. “In the future, AstraZeneca (China) will be a fully integrated platform company with strong strengths in all areas of  ailments, and Tigermed will undoubtedly be one of the most important partners on this platform,” he said. “This strategic cooperation is also another strategic innovative measure after China Business Innovation Center and support to build Wuxi International Life Science Innovation Park.”

On this cooperation, Dr. Ye Xiaoping, chairman of Tigermed, said: “AstraZeneca, as an innovation-driven global integrated biopharmaceuticals company, has performed well in supporting and promoting new drug research and development, and business model innovation in recent years. Tigermed focuses on providing clinical research-related services for innovative drugs, promoting the commercialization of innovative products. Both organizations are committed to the commercialization of innovative pharmaceutical products, thus contributing to the cause of human health, can be said to be like-minded. Prior to this, AstraZeneca fully supported Wuxi Municipal Government and Wuxi High-tech Zone to build Wuxi International Life Science Innovation Park. Tigermed also became the first partner of the Innovation Park. This cooperation is based on the strategic advancement of many previous important cooperation. Tigermed will give full play to its professional service ability and rich experience in innovative drug research and development in the whole process of clinical research, so as to help AstraZeneca further accelerate the research and development of pharmaceutical innovation for the benefit of more patients. “

About AstraZeneca in China

Since entering China in 1993, AstraZeneca has been committed to meeting China’s increasing healthcare needs by continuously following the science and focusing on innovation, becoming China’s most trusted healthcare partner bringing forth innovative solutions to improve the lives of Chinese patients. AstraZeneca’s China headquarters are located in Shanghai, and the company has approximately 13,000 employees throughout China. We’ve established manufacturing sites in Wuxi and Taizhou, Jiangsu, as well as a China Distribution Centre in Wuxi. In China, AstraZeneca focuses on therapeutic areas that local patients’ needs most: respiratory, cardiovascular, metabolic, oncology, gastrointestinal and renal disease. In 2017, AstraZeneca China Commercial Innovation Center was established in Wuxi, with the aim to explore innovative IoT-based integrated diagnosis and treatment solutions. In the same year, AstraZeneca cooperated with SDIC Fund in establishing Dizal Pharmaceutical so as to accelerate local development of innovative medicines. In 2019, AstraZeneca announced its support for the building of the Wuxi International Life Science Innovation Park by the Wuxi municipal government and Wuxi Hi-tech District, to bring global wisdom for patients in China.

About Tigermed

Hangzhou Tigermed Consulting Co., Ltd(stock symbol: 300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 32 subsidiaries, 95 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Korea, Australia, Japan, Malaysia, Singapore , India and Romania with over 4100 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China,owning to our involvement of over 150 innovative drugs.